Koo asked "However would you not agree that if RVX was trading on Nasdaq it would be a different ballgame with respect to share price?"

We would surely get more exposure. However, we all know how the stock markets, especially Nasdaq, have fared so far in Q1 2016.....quite a bloodbath for most.

Speaking of exposure:

1) Just this week, the RVX-208 article that was accepted into the Atherosclerosis Journal as an "Article in Press" was assigned to the future April 2016 print issue. This seems to be a normal progression for this journal. However, as of this morning it is not indexed yet on PubMed. It will probably be indexed there in the next few days.

From the PubMed Help Page, "PubMed is a free resource that is developed and maintained by the National Center for Biotechnology Information (NCBI), at the U.S. National Library of Medicine (NLM), located at the National Institutes of Health (NIH). Publishers of journals can submit their citations to NCBI and then provide access to the full-text of articles at journal web sites."

I looked at a few other recent Atherosclerosis articles that moved from the "Article in Press" stage to an assigned issue, and it seems that shortly after this happens it gets indexed on NCBI. So we should see it indexed on PubMed/NCBI very shortly. So right now, very likely only a select few people who specifically follow RVX or that journals table of contents even know about this paper. So right now, unless one specifically does a general internet search for RVX-208, etc, or gets RVX news feeds, or regularly checks the Atherosclerosis Articles in Press, then they won't really know about this publication.

Speaking as a scientist, it is hard to find an article if I can't get it on PubMed. Many scientific publication search engines rely on NCBI/PubMed to give regular search results. If one can't find it there, it is more or less non-existent unless one uses one of the other search methods I mentioned above. So I am confident that more exposure in the scientific community will occur once this article gets indexed on PubMed. Of course, exposure doesn't equate to excitement or movement in share price, so it is yet to be seen what happens.

2) I am super excited about the Epigenetics: Cancer and Beyond meeting in late April that Don McCaffrey and Norman Wong are helping to organize. Both Ewelina Kulikowski and Eric Campaue will be speaking on behalf of Resverlogix and Zentih, and the rest of the speaker panel are solid epigenetics researcher from Academia or Industry (Constellation) with many of them Bromodomain/BRD4 researchers. Looks like this meeting is sponsored by the journal Nature........so a lot of exposure potential there. It's still 2 1/2 months away, but I think this meeting has the potential to make a lot of noise. Of course, by them we should have had our Q1 RVX webcast and hopefully the Zenith prostate cancer trial will have kicked off......but still it is a great opportunity to showcase both companies!

BearDownAZ